Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Innate and Acquired Transcriptional Programs Shape Heterogeneous Tumor Cell Responses to PARP, Akt, and CDK4/6 Inhibitors

ABSTRACT: Targeted therapies are increasingly utilized across cancer types, yet their efficacy in triple-negative breast cancer (TNBC) remains limited due to the disease’s high heterogeneity and aggressive nature. In a heterogeneous tumor, treatment failure can occur due to the presence of therapy-tolerant cells, which may either be innately drug-tolerant or readily adaptive to therapy cytotoxicity. To investigate how transcriptomic heterogeneity influences response and adaptation to targeted therapy in TNBC, this study leverages the ClonMapper cell barcoding system combined with single-cell RNA sequencing (scRNA-seq) to track differential responses of DNA barcoded clonal subpopulations during treatment with PARP-, Akt-, and CDK4/6-targeting therapy. For the three different targeted therapies, distinct innate and acquired gene signatures, unique to each therapy type, are shown to be predictive of a cell’s level of persistence during treatment. This work demonstrates that non-genetic heterogeneity plays a central role in response and resistance to targeted therapy, highlighting the need to consider tumor heterogeneity to guide effective use of targeted chemotherapy in TNBC.

ORGANISM(S): Homo sapiens

PROVIDER: GSE328823 | GEO | 2026/05/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genome-wide loss-of-function CRISPR/Cas9 screen of Triple Negative Breast Cancer GSI-resistant MB157R cells treated with GSI or vehicle.

Project description:Cell plasticity of Triple negative breast cancer (TNBC) contributes to tumor heterogeneity and is one of the major reasons for the limited success of chemo- or combination therapies in the clinics. The molecular mechanisms of therapy-induced tumor cell plasticity and associated resistance to chemo or targeted therapies are largely unknown. Using a genome wide CRISPR-Cas9 screen we investigated the escape mechanisms of Notch driven TNBC, when treated with targeted therapy. We describe molecularly a reciprocal inhibitory feedback mechanism between Notch signaling and the pluripotency associated transcription factor SOX2, which shapes divergent cell states, EMT, cancer stem cell features and associates with therapeutic response and escape to targeted therapy. Moreover, we performed and assessed monotherapy and drug combination treatments in Notch-inhibitor sensitive and resistant TNBC xenotransplant and identified combination and second line treatment options which were able to induce tumor control and reduce metastatic burden.

2024-10-25 | GSE270368 | GEO

Chromatine immunoprecipitation (ChIP-seq) for RBPJ and SOX2 in Triple negative breast cancer MB157 cells and GSI-resistant MB157R cells upon induction of Notch1 or Sox2 signaling.

2024-10-25 | GSE262007 | GEO

Gene expression profiling of Triple Negative Breast Cancer MB157 cells and GSI-resistant MB157R cells upon induction of Notch1 or Sox2 signaling.

2024-10-25 | GSE262001 | GEO

Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in NSCLC (scRNA-Seq)

Project description:Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alterations in EGFR, ALK and KRAS. The success of targeted therapy is limited by drug-tolerant persister cells (DTPs) which withstand and adapt to treatment and comprise the residual disease state that is typical during treatment with clinical targeted therapies. Here, we integrate studies in patient-derived and immunocompetent lung cancer models and clinical specimens obtained from patients on targeted therapy to uncover a focal adhesion kinase (FAK)-YAP signaling axis that promotes residual disease during oncogenic EGFR-, ALK-, and KRAS-targeted therapies. FAK-YAP signaling inhibition combined with the primary targeted therapy suppressed residual drug-tolerant cells and enhanced tumor responses. This study unveils a FAK-YAP signaling module that promotes residual disease in lung cancer and mechanism-based therapeutic strategies to improve tumor response.

2024-02-29 | GSE260499 | GEO

Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in NSCLC

2024-02-20 | GSE255958 | GEO

Gene expression proﬁling of MDA-MB-231 cells treated Compound 28, a CDK9 degrader

Project description:Triple-negative breast cancer (TNBC) is highlyaggressive with very limited treatment options due to the lack of eﬃcient targeted therapies and thus still remains clinically challenging. Targeting CDK9 to remodel transcriptional regulation shows great promisein cancer therapy. We synthesized new series of heterobifunctional molecules ashighly selective and eﬃcacious CDK9 degraders, enabling potentinhibition of TNBC cell growth and rapidly targeted degradationof CDK9. Moreover, the CDK9 degrader (compound 28) was used to treat on TNBC cell lines and the gene expression profile was performed by RNA-seq.

2024-11-27 | GSE282602 | GEO

Comprehensive proteomic characterization reveals subclass-specific molecular aberrations within triple-negative breast cancer

Project description:Triple-negative breast cancer (TNBC) is regarded as the most aggressive subtype of breast cancer lacking targeted therapies. This is attributed to its high heterogeneity that complicates elucidation of its molecular aberrations. Here, we report identification of specific proteome expression profiles pertaining to two TNBC subclasses, basal A and basal B, through in-depth proteomics analysis of breast cancer cells. We observed that kinases and proteases displayed unique expression patterns within the subclasses, similar to whole proteome clusters. Systematic analyses of protein-protein interaction and co-regulation networks of these kinases and proteases unraveled dysregulated pathways and plausible targets for each TNBC subclass. Among these, we identified kinases AXL, PEAK1 and TGFBR2, and proteases FAP, UCHL1 and MMP2/14, as specific targets for basal B subclass, which represents the more aggressive TNBC cell lines. Our study thus highlights intricate mechanisms and distinct targets within TNBC, and emphasizes that these have to be exploited in a subclass-specific manner rather than a one-for-all TNBC therapy.

2020-03-03 | PXD017025 | Pride

Impact of Depletion or Overexpression on Gene Expression in Triple Negative Breast Cancer

Project description:Triple-negative breast cancer (TNBC), known for its aggressiveness and high lethality, presents a significant challenge in terms of treatment. Its heterogeneity and absence of hormone receptors or HER2 expression further limit the availability of targeted therapies. Breast cancer stem cells (BCSCs), recognized for their role in fueling TNBC malignancy, are now being targeted as a vulnerability for TNBC treatment. In this study, we analyzed the transcriptome of BCSCs and identified Kinesin Family Member 20A (KIF20A) as an essential gene for BCSC survival and TNBC tumorigenesis. Depletion or pharmacological inhibition of KIF20A impairs BCSC viability, tumor initiation, and development both in vitro and in vivo. Mechanistically, KIF20A regulates BCSC stemness by modulating the oxidative phosphorylation (OXPHOS) pathway in mitochondria. Our findings underscore the importance of targeting KIF20A as a strategy to exploit BCSC vulnerability in TNBC.

2025-12-31 | GSE265795 | GEO

Identification of a shared drug-tolerant persister program in triple-negative breast cancer across treatments and patients [CUT&Tag]

Project description:Acquisition of resistance to anti-cancer therapies is a multistep process, which initiates with the survival of drug tolerant persister cells. Understanding the mechanisms driving the emergence of drug tolerant persister cells remains challenging, primarily because of their limited accessibility in patients. Here, using multiple patient-derived models to isolate persister cells, we show these cells are transcriptionally plastic in vivo and return to a common treatment-naïve like state upon relapse, regardless of the treatment they have been exposed to. We reveal hallmarks of the persister state in TNBC across treatment modalities: high expression of basal keratins together with activation of a stress response and inflammation pathways. HER2+ breast and lunger cancer cells also activate these hallmarks of drug tolerance in response to targeted therapies. Leveraging gene regulatory networks, we identify AP-1, NFKB and IRF/STAT as the key drivers of this hallmark persister state. As a proof of concept, we show that FOSL1 - an AP-1 member - is sufficient to drive cells to the persister state by binding enhancers and reprogramming the transcriptome of cancer cells. On the contrary, cancer cells without FOSL1 have a decreased ability to reach the persister state. By defining hallmarks of drug persistence to multiple therapies of the standard of care in TNBC, our study provides a resource to design novel combination therapeutic strategies to limit resistance.

2025-09-22 | GSE280454 | GEO

Identification of a shared drug-tolerant persister program in triple-negative breast cancer across treatments and patients [CITE-seq]

2025-09-22 | GSE280455 | GEO